Dynamics of biological markets with multiple biosimilar competitors in the United States
Very few originator biologics have multiple available biosimilar competitors. Barrier to biosimilar availability seems to be at the approval level as the time between approval and launch is relatively short. However, originator biologics respond quickly to biosimilar competition, mainly through an increase in rebates.
Authors
- Mariana P. Socal (ORCID: https://orcid.org/0000-0001-9459-4898)
- Morgane C. Mouslim (ORCID: https://orcid.org/0000-0002-6999-7588)
- Antonio J. Trujillo (ORCID: https://orcid.org/0000-0002-0800-8512)
Institutions
- Johns Hopkins University (US)
- University of Maryland, Baltimore County (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1080/14712598.2024.2412648
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Arnold Ventures